Der er ikke foretaget studier for at undersøge bevacizumabs farmakokinetik hos patienter med nedsat leverfunktion, idet metabolismen og udskillelsen af bevacizumab i det væsentlige ikke finder sted i leveren.
No studies have been conducted to investigate the pharmacokinetics of bevacizumab in patients with hepatic impairment since the liver is not a major organ for bevacizumab metabolism or excretion.